What is the debt of Antigenics this year?
Antigenics has a debt level of 0 USD this year.
Antigenics Debt 2025
Antigenics Debt
0 USD
Ticker
ANTI
ISIN
US0370311013
WKN
932075
In 2025, Antigenics's total debt was 0 USD, a 0% change from the 0 USD total debt recorded in the previous year.
Antigenics Aktienanalyse
What does Antigenics do?
Antigenics Inc, now Agenus Inc, is a biotechnology company specializing in the research and development of innovative therapies for cancer and infectious diseases. The company is headquartered in Lexington, Massachusetts. The history of Antigenics begins in the late 1980s when the founder, Garo Armen, developed a method for identifying DNA sequences that encode specific proteins. The approach was based on the isolation of lentiviral vectors from human cells, which were then used to transfer the DNA sequences to other cells. This method allowed Antigenics to identify a variety of tumor-specific antigens (TSA) that could serve as potential targets for immunotherapies. In the 1990s, Antigenics focused on developing anti-tumor vaccines based on TSA. The first product was Oncophage, a vaccine made from individual TSA peptides isolated from the patient's tumor cells. Oncophage was tested in Phase II clinical trials in patients with various forms of cancer, including melanoma, renal cell carcinoma, and glioblastoma. Although the vaccine showed significant survival benefits in some studies, it was not approved in the United States. Today, Oncophage is used in Russia and India for the treatment of kidney cancer. In the late 2000s, Antigenics expanded its portfolio to include other immune-oncology approaches such as immune checkpoint protein CTLA-4 modulators, cytotoxic antibodies against cancer cells, and small molecules for immune activation. In 2014, the company was renamed Agenus Inc to reflect its expanded business model. Today, Agenus focuses on the development of immune combination therapies that combine various approaches to activate and modulate the immune system to achieve synergistic effects. The focus is on the use of immune checkpoint inhibitors that relieve T-cell inhibition, as well as the combination of vaccines and cytotoxic antibodies. Agenus' current products include immune checkpoint inhibitor CTLA-4 Ig, which is being tested in Phase III clinical trials for melanoma and lung cancer, and the QS-21 vaccine, which elicits a strong immune response and is used as an adjuvant for other vaccines for the treatment of infectious diseases. Agenus has various divisions, including a division for veterinary immunotherapies, which specializes in the development of vaccines and treatment methods for dogs and horses with cancer. Overall, Agenus has a rich history in the research and development of immunotherapies for the treatment of cancer and infectious diseases. Although the company has experienced setbacks in the past, it remains a key player in the field of immune-oncology and is expected to develop further groundbreaking therapies. Antigenics ist eines der beliebtesten Unternehmen auf Eulerpool.com.Debt Details
Understanding Antigenics's Debt Structure
Antigenics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Year-to-Year Comparison
Analyzing Antigenics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Impact on Investments
Investors pay close attention to Antigenics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Interpreting Debt Fluctuations
Shifts in Antigenics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Frequently Asked Questions about Antigenics stock
What was the debt of Antigenics compared to the previous year?
The debt of Antigenics has increased by 0% compared to the previous year dropped.
What are the consequences of high debt for investors in Antigenics?
High debt can pose a risk for investors of Antigenics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
What are the consequences of low debt for investors of Antigenics?
Low debt means that Antigenics has a strong financial position and is able to fulfill its obligations without overburdening its finances.
How does an increase in debt from Antigenics affect the company?
An increase in debt of Antigenics can adversely affect the financial condition of the company and result in a higher burden on its finances.
How does a reduction of debt of Antigenics affect the company?
A reduction in debt of Antigenics can strengthen the company's financial position and improve its ability to meet its financial obligations.
What are some factors that influence the debt of Antigenics?
Some factors that can influence the debt of Antigenics include investments, acquisitions, operating costs, and revenue development.
Why are the debts of Antigenics so important for investors?
The debts of Antigenics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
What strategic measures can Antigenics take to change the debt?
To change the debt, Antigenics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
How much dividend does Antigenics pay?
Over the past 12 months, Antigenics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Antigenics is expected to pay a dividend of 0 USD.
What is the dividend yield of Antigenics?
The current dividend yield of Antigenics is .
When does Antigenics pay dividends?
Antigenics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Antigenics?
Antigenics paid dividends every year for the past 0 years.
What is the dividend of Antigenics?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Antigenics located?
Antigenics is assigned to the '-' sector.
Wann musste ich die Aktien von Antigenics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Antigenics from 5/31/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/31/2025.
When did Antigenics pay the last dividend?
The last dividend was paid out on 5/31/2025.
What was the dividend of Antigenics in the year 2024?
In the year 2024, Antigenics distributed 0 USD as dividends.
In which currency does Antigenics pay out the dividend?
The dividends of Antigenics are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Antigenics
Our stock analysis for Antigenics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Antigenics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.